Skip to main content
SpringerLink
Log in

RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do

  • ONCOLOGY (S DELORME, SECTION EDITOR)
  • Published:
Current Radiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aims to give a brief update how to do RECIST 1.1, irRECIST 1.1, and mRECIST.

Recent Findings

The revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are currently representing the most commonly used and validated response criteria for objective treatment monitoring of conventional chemotherapies in solid tumors. However, with the introduction of novel molecular drugs and local tumor therapies, such as selective transarterial chemoembolization (TACE) at hepatocellular carcinomas (HCC), limitations of the conventional RECIST 1.1 became obvious due to specific response pattern, which are not reflected. Thus, for a comprehensive evaluation of immunotherapeutic agents new immune-related RECIST (irRECIST 1.1) and of selective HCC treatment modified RECIST (mRECIST) criteria have been published.

Summary

RECIST 1.1 presents the most used response criteria for conventional chemotherapies in solid tumors. For specific evaluation of immunotherapeutic agents irRECIST 1.1 and of selective HCC treatment mRECIST have been established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. WHO. WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva; 1979.

  2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16. doi:10.1093/jnci/92.3.205.

    Article  CAS  PubMed  Google Scholar 

  3. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026.

    Article  CAS  PubMed  Google Scholar 

  4. Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261–7. doi:10.1016/j.ejca.2008.10.028.

    Article  CAS  PubMed  Google Scholar 

  5. • Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17. doi:10.1186/2051-1426-2-17. Original publication of irRECIST 1.1.

  6. • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132. Original publication of mRECIST for HCC.

  7. Hodi FS, O’Day S, McDermott DF, Weber RW, Sosman J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:2255–65. doi:10.1056/NEJMoa1207290.

    Article  Google Scholar 

  8. Spiro J, Maintz D, Persigehl T. Responsekriterien bei malignem Melanom—RECIST und irRC. Radiologe. 2015;2:127–35. doi:10.1007/s00117-014-2763-y.

    Article  Google Scholar 

  9. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. doi:10.1158/1078-0432.CCR-09-1624.

    Article  CAS  PubMed  Google Scholar 

  10. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936–43. doi:10.1158/1078-0432.CCR-13-0895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kim MN, Kim BK, Han K-H, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015;9:335–48. doi:10.1586/17474124.2015.959929.

    Article  CAS  PubMed  Google Scholar 

  12. Hyun D, Shin SW, Cho SK, Park KB, Park HS, et al. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol. 2015;56:1437–45. doi:10.1177/0284185114560937.

    Article  PubMed  Google Scholar 

  13. Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16–22. doi:10.3109/03009734.2012.729104.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Shim JH, Lee HC, Kim S-O, Shin YM, Kim KM, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–18. doi:10.1148/radiol.11110282.

    Article  PubMed  Google Scholar 

  15. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147–56. doi:10.1002/cncr.26255.

    Article  CAS  PubMed  Google Scholar 

  16. ACR. American College of Radiology - Liver Imaging Reporting and Data System version 2014. 2014. https://nrdr.acr.org/lirads/.

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany

    Joern Henze, David Maintz & Thorsten Persigehl

Authors
  1. Joern Henze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Maintz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thorsten Persigehl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Persigehl.

Additional information

This article is part of the Topical Collection on Oncology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henze, J., Maintz, D. & Persigehl, T. RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do. Curr Radiol Rep 4, 48 (2016). https://doi.org/10.1007/s40134-016-0178-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s40134-016-0178-4

Keywords

Search

Navigation